SATURDAY 13 April 2019

Keynote lectures

13:30-14:30, Hall A
Jean-Michel Molina (France)
*Biomedical prophylaxis of HIV and other sexually transmitted infections: a change of paradigm?*

14:45-15:45, Hall A
EXCELLENCE AWARD LECTURE
Ron Dagan (Israel)
*PCVs: the first vaccines against normal nasopharyngeal microbiota constituents*

SATURDAY 13 April 2019

Meet-the-Expert sessions

8:45-9:45, Hall G
How to deal with antimicrobial drug and vaccine shortages?
co-organised with ESCMID Study Groups ESGAP and EVASG
Guillaume Beraud (Canada)
Larissa May (United States)

8:45-9:45, Hall L
How to manage and treat Crimean-Congo and other haemorrhagic fevers
co-organised with the Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD)
Nurcan Baykam (Turkey)
Marta Mora-Rillo (Spain)
SATURDAY 13 April 2019

Symposia

10:00-11:00, Hall M
Prevention of infections in surgical patients due to multidrug-resistant Gram-negatives
co-organised with ESCMID Study Groups ESGNI, ESGCP, ESGITM and ESGVH
Maristela P. Freire (Brazil)
Carbapenem resistance in donors and recipients of organ transplants: consequences for patients and healthcare personnel
Benedikt Huttner (Switzerland)
Surgical prophylaxis in patients colonised with multidrug-resistant Gram-negative bacteria

10:00-12:00, Hall F
Automation and artificial intelligence in nosocomial infection prevention
Fidelma Fitzpatrick (Ireland)
Automation in hand hygiene surveillance and improvement
Philip M. Polgreen (United States)
Computer vision monitoring of infection prevention practices
Maaike S. M. van Mourik (Netherlands)
Fully automated healthcare-associated infection surveillance: how do we get there?
Erica S. Shenoy (United States)
Prediction for prevention: applied machine learning to identify risk of healthcare associated infections

10:00-11:00, Hall K
Microbiology by DNA: moving towards clinical metagenomics
Etienne Ruppe (France)
Promises and hurdles of metagenomics
Teresa Street (United Kingdom)
Clinical metagenomics in bone and joint infections
Charles Chiu (United States)
Metagenomics to unveil undetected microorganisms
Liana Kafetzopoulou (Belgium)
Clinical metagenomics in the field: outbreak investigation in limited-resource settings

10:00-12:00, Hall D
Management of chronic bone and joint infections
co-organised with the ESCMID Study Group ESGIAI
Chair: Robin Patel (United States)
Frédéric Laurent (France)
Chronic bone and joint infection: how bacteria remain alive in bone environment?
Marjan Wouthuysen-Bakker (Netherlands)
Suppressive antibiotic treatment for implanted-associated infections: Pros and cons
Ho K. Li (United Kingdom)
What have we learnt from the OVIVA trial on duration and route of antibiotic administration?
Tristan Ferry (France)
Alternative options to rescue patients: novel anti-persister antibiotics, local antibiotic delivery, phage therapy
SATURDAY 13 April 2019

Symposia

10:00-12:00, Hall B
The last bastion of AMR: heteroresistance in multidrug-resistant Gram-negative pathogens
co-organised with the ESCMID Study Group ESGARS
Wellcome Data Re-use Prize – AMR Surveillance: winner announcement
Luis Martinez-Martinez (Spain)
Heteroresistance: selection of mutants versus persistence
Spyros Pournaras (Greece)
Heteroresistance to antibiotics in multiresistant Acinetobacter baumannii
Jean-Marco Rolain (France)
Colistin heteroresistance in carbapenem-resistant Klebsiella pneumoniae
Nathalie Questembert-Balaban (Israel)
Methods for in vitro study of bacterial heteroresistance

13:30-14:30, Hall J
Breaking the limits: innovation in the treatment of HIV/AIDS
co-organised with the European AIDS Clinical Society (EACS)
Chair: Anna Maria Geretti (United Kingdom)
Dan Barouch (United States)
Neutralising antibodies: from laboratory to clinical practice
Jose Arribas (Spain)
Antiretroviral treatment challenges: the future of long-acting formulations

13:30-14:30, Hall G
Top papers in paediatric infectious diseases and vaccines
co-organised with the ESCMID Study Group EVASG
Adam Finn (United Kingdom)
Vaccines
Helen Marshall (Australia)
Paediatric infectious diseases

13:30-14:30, Hall C
Taking a pill, a risky gesture? Unexpected effects of non-antibiotic medications on commensal and pathogenic bacteria
Kiran R. Patil (Germany)
Impact of non-antibiotic drugs on the human gut microbiome
Geraint Rogers (Australia)
Cancer chemotherapy as a driver of antimicrobial resistance

13:30-14:30, Hall N
Looking beyond the usual suspect: an update on respiratory mycobiome
co-organised with ESCMID Study Groups ESGAMI and EFISG
Emily Cope (United States)
Respiratory mycobiome in chronic airway inflammatory diseases and emerging relationships with the host immune response
Robert Krause (Austria)
Respiratory mycobiome: a clinical perspective
**SATURDAY 13 April 2019**

**Symposia**

13:30-14:30, Hall F  
*Top papers in neglected tropical diseases and migrant health*  
co-organised with ESCMID Study Groups ESGITM and ESGCP  
Ujjala Ghoshal (India)  
*Tropical diseases*  
Ymkje Stienstra (Netherlands)  
*Migrant health*

14:45-15:45, Hall M  
*Imaging of infection with next generation microscopy*  
co-organised with ESCMID Study Groups ESGS and ESGB  
Bas Surewaard (Canada)  
*Visualizing novel anti-Staphylococcal treatment options using intravital microscopy*  
Jessica Mark Welch (United States)  
*FISH for microbial structures*

16:00-17:00, Hall N  
*Microbiota and transplantation*  
co-organised with ESCMID Study Groups ESGHAMi and ESGICH  
Eric G. Pamer (United States)  
*How microbiota influences stem-cell transplantation*  
Maria-Luisa Alegre (United States)  
*How microbiota influences solid-organ transplantation*

16:00-18:00, Hall K  
*From single cells to biofilm populations in the host micro-environment*  
co-organised with the ESCMID Study Group ESGB  
Thomas Bjarnsholt (Denmark)  
*The micro-environment of chronic infections and its influence in biofilm persistence*  
Thien-Fah Mah (Canada)  
*Transcriptional regulation of antibiotic resistance mechanisms in Pseudomonas aeruginosa biofilms*  
Angelika Gründling (United Kingdom)  
*Mechanistic insights into nucleotide signalling pathways in Staphylococcus aureus*  
Guillaume Duménil (France)  
*Species-independent attraction to biofilm through electronic signalling*

16:00-18:00, Hall B  
*New strategies to deliver antibiotics into bacteria*  
Paula Gameiro (Portugal)  
*Antibiotic-metal complexes: a strategy to overcome bacterial resistance?*  
Gaëtan Mislin (France)  
*Development and vectorization of innovative organometallics against pathogenic bacteria*  
Marvin J. Miller (United States)  
*Vectorisation of Gram-positive antibiotics into Gram-negative bacteria*  
Mariena van der Plas (Denmark)  
*Novel peptide-based anti-infective concepts for a post-antibiotic era*
SATURDAY 13 April 2019

Symposia

16:00-18:00, Hall J
Respiratory antivirals: advancing clinical research and surveillance in different age and risk groups
co-organised with the ESCMID Study Group ESGREV
Frederick G. Hayden (United States)
What’s new in respiratory antivirals?
Jacques Demotes (France)
Developing clinical trials infrastructure
Pasi Penttinen (Sweden)
Assessing the “real-world” impact of antivirals in Europe
Prabha Viswanathan (United States)
Measuring clinical and virologic outcomes in different age and risk groups

16:00-18:00, Hall H
Diagnostic stewardship: making the most out of diagnostic opportunities
Brigitte Lamy (France)
Monitoring and quality indicators in blood culture processing
Nancy Cornish (Unites States)
Impact of structured pre-analytic algorithms on diagnostic quality
Serap S. Yavuz (Turkey)
When PCR makes sense: go and no-go in molecular testing
Martin Christner (Germany)
Choosing wisely: essential role of computerised provider order entry systems in infection diagnostics

SATURDAY 13 April 2019

Symposia

16:00-18:00, Hall C
Focus on streptococcal infections: compelling questions and emerging answers
Anne Botteaux (Belgium)
Changing Group A streptococcal infections: emerging or re-emerging clones
Claire Poyart (France)
Group B Streptococcus: why did it emerge to be the major pathogen responsible for neonatal infection?
E. A. M. Sanders (Netherlands)
Streptococcus pneumoniae: impact of vaccination on nasopharyngeal microbiota
Shaynoor Dramsi (France)
Group D Streptococcus gallolyticus: an old pathogen responsible for endocarditis often underestimated

16:00-18:00, Hall G
Open questions in clinical mycology: do we have new answers?
Maurizio Sanguinetti (Italy)
Rapid diagnosis of drug-resistant Candida
Kieren Marr (United States)
Diagnosis of aspergillosis: advances in technologies and approach
Carolina Garcia Vidal (Spain)
Breakthrough fungal infections: not only Aspergillus!
Dionysios Neofytos (Switzerland)
Fungal infection related to new immunotherapies and biologicals
SATURDAY 13 April 2019

Educational Workshops

10:00-12:00, Hall I
Zoonotic species identification with MALDI-TOF MS
cocOrganised with ESCMID Study Groups ESGVM, ESGMD and ESGPHM
Birgitta Duim (Netherlands)
Evaluation of MALDI-TOF MS for the identification of coagulase-positive staphylococcal species within the Staphylococcus intermedius group
Belen Rodriguez-Sanchez (Spain)
Identification of “difficult bacteria” made easy
Peter Lasch (Germany)
Safety and accuracy of MALDI-TOF MS for the identification of highly pathogenic microorganisms
Interactive panel discussion

10:00-12:00, Hall E
Applying pharmacokinetic/pharmacodynamic principles in critically ill patients
cocOrganised with the Trainees Association of ESCMID (TAE) and the ESCMID Study Groups EPASG and ESGCIP
Elisabet Nielsen (Sweden)
Factors leading to alterations in PK/PD of antimicrobials in critically ill patients
Matteo Bassetti (Italy)
What is the type of critically ill patients at risk of multidrug resistance?
Jason Roberts (Australia)
How to optimise antibiotic administration in critically ill patients: from PK/PD to TDM
Interactive panel discussion

SATURDAY 13 April 2019

Educational Workshops

8:45-12:45, Hall A
Antimicrobial susceptibility testing (AST) with EUCAST methods and breakpoints
cocOrganised with the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
Christian Giske (Sweden)
EUCAST news
Gunnar Kahlmeter (Sweden)
Redefining susceptibility categories and introducing areas of technical uncertainty
Johan Mouton (Netherlands)
Challenging drugs for AST: e.g. fosfomycin, polymyxins
Erika Matuschek (Sweden)
Challenging bugs for AST: e.g. H. influenzae
Matthew Ellington (United Kingdom)
Whole genome sequencing in AST: what’s new?
Qiwen Yang (China)
EUCAST around the world
Maiken C. Arendrup (Denmark)
Antifungal Subcommittee update
Interactive panel discussion
SATURDAY 13 April 2019

**Oral sessions**

10:00-12:00, Hall C  
*Entering the era of new pneumococcal vaccines*

10:00-12:00, Hall G  
*Using new tools to identify and measure healthcare-associated infections*

10:00-12:00, Hall H  
*Issues in antifungal treatment*

10:00-12:00, Hall J  
*The new era in *C. difficile* infection*

10:00-12:00, Hall L  
*Intestinal parasites*

10:00-12:00, Hall I  
*Outpatient antibiotic prescribing and ways to improve it*

13:30-14:30, Hall B  
*Controlling *C. difficile* in and out of the hospital*

14:45-15:45, Hall C  
*Managing bacterial infections in the tropics*

14:45-15:45, Hall F  
*HPV Testing: beyond testing the cervix*

14:45-15:45, Hall G  
*Microbiome across the lifespan*

14:45-15:45, Hall H  
*Rapid AST: options and successes*

14:45-15:45, Hall J  
*PK/PD to predict emergence of resistance*

14:45-15:45, Hall N  
*Molecular diagnosis of parasitic diseases*

14:45-15:45, Hall K  
*Molecular diagnosis of parasitic diseases*
SARURDAY 13 April 2019

MiniOral ePoster sessions

13:30-14:30
Antibacterial activity of unusual combinations

13:30-14:30
Antibiotic consumption and prescription: quality measures

13:30-14:30
Diagnostic bacteriology: we still rely on culture

13:30-14:30
All you need for your lab automation!

14:45-15:45
Respiratory viruses: what's out there and what do they mean?

14:45-15:45
Beta-lactamase inhibitors: the "second generation" meets the "first generation" problems

14:45-15:45
Assessing the burden and consequences of healthcare-associated infections

14:45-15:45
Clinical trials with recently approved or late-stage development antibiotics

SUNDAY 14 April 2019

Keynote lectures

11:00-12:00, Hall A
Trevor Lawley (United Kingdom)
The spreading of health: transmission of commensal bacteria

14:45-15:45, Hall A
Victor Nizet (United States)
Collaborating with the innate immune system to treat antibiotic-resistant superbugs

“Year in…”

11:00-12:00, Hall H
Year in Clinical Microbiology
Emilia Cercenado (Spain)
Marion P. G. Koopmans (Netherlands)

13:30-14:30, Hall A
Year in Infectious Diseases
Pierre Tattevin (France)
Cristina Mussini (Italy)
SUNDAY 14 April 2019

Meet-the-Expert

7:30-8:30, Hall F
Changing my laboratory: drivers and critical parameters of the process
Suzan D. Pas (Netherlands)
François Vandenesch (France)

7:30-8:30, Hall N
Making sense of genome shreds: tools and strategies for straightforward genome data analysis
co-organised with the ESCMID Study Groups ESGEM and ESGMD
David Aanensen (United Kingdom)
Natacha Couto (Netherlands)

7:30-8:30, Hall E
Decision-making in the detection and management of patients with sepsis and critical illness in resource-limited settings
Mervyn Mer (South Africa)
Gentle Sunder Shrestha (Nepal)

7:30-8:30, Hall D
How to treat diabetic foot infections in view of new guidance?
co-organised with the Turkish Society of Clinical Microbiology and Infectious Diseases (KLIMIK)
Mustafa B. Ertuğrul (Turkey)
Ilker Uçkay (Switzerland)

7:30-8:30, Hall G
Difficult treatment scenarios in transplant patients with opportunistic viral infections: a case-based approach
Irit Avivi (Israel)
Roy Chemaly (United States)

SUNDAY 14 April 2019

Symposia

8:45-10:45, Hall K
Addressing burning questions in the management of community-acquired pneumonia (CAP)
Kate Templeton (United Kingdom)
Gaps in rapid diagnosis of CAP pathogens
Rosario Menendez (Spain)
What are the predictors of treatment failure and how should the non-responding patient be approached?
Thomas File (United States)
Antibiotic therapy: how long is enough?
Jordi Carratala (Spain)
How great is the burden of acute cardiac events in pneumonia patients and how can they be prevented?

8:45-10:45, Hall B
Monotherapy or antibiotic combination therapy for Staphylococcus aureus infection: time for a change?
co-organised with ESCMID Study Groups ESGS and ESGBIES
Annelies Zinkernagel (Switzerland)
Do we have convincing preclinical data on mono- versus combination therapy?
Miguel Pujol (Spain)
What did and didn’t we learn from clinical trials of combination therapy?
Steven Y. C. Tong (Australia)
Which trial designs are needed to address optimised therapy of S. aureus bloodstream infection?
Ruth Massey (United Kingdom)
Using genomics to understand the interplay between pathogenicity, virulence and antibiotic resistance
SUNDAY 14 April 2019

Symposia

8:45-10:45, Hall A
Manipulating microbiota for infection prevention
co-organised with ESCMID Study Groups ESGNI and ESGCIP
Emine Alp Mese (Turkey)
*Probiotics for the prevention of ventilator-associated pneumonia: where is the evidence?*
James Hurley (Australia)
*Impact of selective decontamination on respiratory microbiota and ventilator-associated pneumonia*
Evelina Tacconelli (Italy)
*Personalised antibiotic therapy to reduce the impact on intestinal microbiota*
Susan S. Huang (United States)
*What we have learned from chlorhexidine and skin cultures and microbiota studies*

8:45-10:45, Hall E
Emerging infections surveillance
co-organised with the ESCMID Task Force for Emerging Infections (EITaF)
David Hamer (United States)
*Travellers as sentinels for emerging disease outbreaks*
Marion P. G. Koopmans (Netherlands)
*Emerging infections preparedness research in a One Health context*
Frank M. Aarestrup (Denmark)
*Urban sewage as a surveillance tool: the global urban sewage project*
Matt Cotten (Netherlands)
*Novel tools for a diagnostic resolution of unexplained disease*

8:45-10:45, Hall I
Antimicrobial tolerance: bacterial stress responses as possible targets for new therapies
Jan Michiels (Belgium)
*Evolutionary and mechanistic aspects of persistence in Escherichia coli and the link with antibiotic resistance*
John D. McKinney (Switzerland)
*Quantitative dynamics of microbial behaviour*
Tanel Tenson (Estonia)
*Stress and toxin-antitoxin systems*
Susan M. Rosenberg (United States)
*Stress-induced mutagenesis*

8:45-10:45, Hall H
What’s new in TB/HIV co-infection?
co-organised with the European AIDS Clinical Society (EACS)
Marieke J. van der Werf
*Characteristics and treatment outcome of TB-HIV co-infection in the European Union*
Richard E. Chaisson (United States)
*New strategies for treatment of latent tuberculosis infection: how low can you go?*
TBA
*Diagnosis and treatment of XDR-TB in HIV-infected patients: is it possible to shorten the duration of treatment?*
Graeme Meintjes (South Africa)
*TB-IRIS: advances in pathogenesis, prevention and management*
SUNDAY 14 April 2019

Symposia

11:00-12:00, Hall B
Possible impact of new immunomodulators on infection and infection management
IDSA-ESCMID joint symposium
Olivier Lambotte (France)
Immune checkpoint inhibitors and infections
Alex Compton (United States)
mTOR inhibitors as broad-spectrum therapeutics: relevance for infection

11:00-12:00, Hall G
The Great Divide: to screen or not to screen for the prevention of early-onset group B Streptococcus disease?
Guduru Gopal Rao (United Kingdom)
The pros of universal screening and Intrapartum Antibiotic Prophylaxis
Miguel Gueimonde (Spain)
The cons of universal screening and Intrapartum Antibiotic Prophylaxis: what are the options?

11:00-12:00, Hall E
Decision making under uncertainty
co-organised with the ESCMID Study Group ESGAP
Steven Hatch (United States)
The tricky problem of uncertainty in medicine with a special focus in infectious diseases
Alexander W. Friedrich (Netherlands)
Overcoming uncertainty in diagnostics

SUNDAY 14 April 2019

Symposia

11:00-12:00, Hall K
Pathogenetic profiling to fight antimicrobial resistance
Christoph M. Ernst (United States)
Identification and targeting of emerging multidrug-resistant Klebsiella pneumoniae pathotypes
Nora Grahl (Germany)
Integration of multi-omics data to unravel antimicrobial resistance mechanisms

13:30-14:30, Hall C
Rapid diagnostic tests in respiratory infections: do they really help clinicians reduce unnecessary antibiotic prescribing?
co-organised with ESCMID Study Groups ESGAP and ESGREV
Kate Templeton (United Kingdom)
Yes, they do!
Sanjay Patel (United Kingdom)
No – no significant effects on prescribing!

13:30-14:30, Hall E
West Nile virus: vectors and animal hosts
Jordi Figuerola (Spain)
European mosquitoes and their implication in West Nile virus biology
Sylvie Lecollinet (France)
Flaviviruses and animals
SUNDAY 14 April 2019
Symposia

13:30-14:30, Hall L
Global health: South American update
co-organised with the Brazilian Society of Infectious Diseases (SBI)
Ana L. Munhoz (Brazil)
Treatment of multi-drug resistant Gram-negative osteomyelitis: experience from the largest Latin American hospital
Ho Yeh Li (Brazil)
Yellow Fever: what we have learned from 2018 outbreak

13:30-14:30, Hall G
“You can teach an old dog new tricks!” – rethinking the zoonotic potential of well-known bacteria
co-organized with ESCMID Study Groups ESGEM and ESGVM
Michael S. Gilmore (United States)
Are enterococci zoonotic bacteria?
Daniel R. Knight (Australia)
New evidence for a zoonotic potential of C. difficile

13:30-14:30, Hall H
Towards the first cancer eradication in humans: joint force of HPV-based screening and HPV vaccination
Mario Poljak (Slovenia)
HPV-based primary screening for cervical cancer: status of implementation
Jorma Paavonen (Finland)
HPV vaccines: lights and shadows

SUNDAY 14 April 2019
Symposia

13:30-14:30, Hall N
Pro/con: optimised dosing according to PK/PD principles in patients - does it improve the efficacy of antibiotics?
Jason Roberts (Australia)
Pro
Marc J. Bonten (Netherlands)
Con

13:30-15:30, Hall K
New antimycobacterial drugs: a hope for drug-resistant tuberculosis
co-organised with the ESCMID Study Group ESGMYC and the endTB project
Christoph Lange (Germany)
Efficacy/safety of bedaquiline and delamanid: evidence from clinical trials
Lorenzo Guglielmetti (France)
New drugs in the pipeline for treatment of multidrug-resistant tuberculosis
Jan W. C. Alffenaar (Netherlands)
High dose rifampicin: should this be routine?
Delia Goletti (Italy)
Host-related markers of response to treatment

14:45-15:45, Hall H
Antibodies in the fight against multidrug-resistant Gram-negative bacterial infection
IDSA-ESCMID joint symposium
Bettina C. Fries (United States)
Antibody-mediated killing of multidrug-resistant Gram-negative bacteria: what’s the future?
Valeria Szijarto (Austria)
Endotoxin neutralization: what’s possible?
SUNDAY 14 April 2019

Symposia

14:45:15:45, Hall B
Climate change and infectious diseases
co-organized with ESCMID Study Groups ESGVM, ESGPHM and ESGBOR
Jan Semenza (Sweden)
The impact of climate change on infectious diseases
Giovanni Rezza (Italy)
Tropical outbreaks in temperate areas

14:45-15:45, Hall E
Thinking out of the box to beat biofilms
Françoise van Bambeke (Belgium)
Activity of drug combinations against staphylococcal biofilms
Sebastian Zaat (Netherlands)
Antimicrobial peptides and medical devices: a very attractive couple

14:45-15:45, Hall L
Optimising antimicrobial use in children: not small adults!
co-organized with the ESCMID Study Group EPASG
Irja Lutsar (Estonia)
PK/PD in children: from models to patients
Julia Bielicki (Switzerland)
What can and did we learn from antibiotic use assessments in paediatric care?

SUNDAY 14 April 2019

Symposia

16:00-18:00, Hall E
Information technology and innovation in infectious diseases
Mehmet Gönen (Turkey)
Machine learning for infectious diseases
Sofia Forslund (Germany)
Multi-omics approaches: towards understanding host-microbiome interactions
TBA
Cheminformatics and complex network analyses: new horizons in infection epidemiology and drug discovery
Carolina Garcia Vidal (Spain)
Applying artificial intelligence to improve empiric antibiotic treatment

16:00-18:00, Hall D
Perspectives on vaccination against respiratory viral infections
co-organised with the ESCMID Study Groups ESGREV and EVASG
Raffael Nachbagauer (United States)
What are the newest developments in next generation influenza virus vaccines?
Odile Launay (France)
Advances in respiratory vaccine effectiveness surveillance: understanding the “real-world” impact
Barbara Rath (Germany)
More effective vaccines against influenza: what and when?
Martin H. Friede (Switzerland)
Life-course approach to immunisation against respiratory viral infections: building trust
SUNDAY 14 April 2019

Symposia

16:00-18:00, Hall A
Hot topics in tuberculosis: from bench to bedside
Joseph Keane (Ireland)
Metabolic changes and host defence against tuberculosis
Jon S. Friedland (United Kingdom)
The impact of the host environment on innate immunity in tuberculosis
Raquel Duarte (Portugal)
Latent tuberculosis and diabetes: a reservoir for future disease and an opportunity for prevention
Giovanni B. Migliori (Italy)
Tuberculosis in vulnerable populations: poverty, migration and imprisonment

16:00-18:00, Hall B
Vaccines: myths and reality
co-organised with the World Association for Infectious Diseases and Immunological Disorders (WAidid)
Manish Sadarangani (Canada)
Historical perspective: what do we know so far on vaccines causing AEFI?
Judith Breuer (United Kingdom)
Live attenuated vaccine strain infection
Paul H. Lambert (Switzerland)
Do vaccines trigger auto-immune diseases?
Results from the prelicensure to post-marketing studies
Julia Stowe (United Kingdom)
Do vaccines trigger neurological diseases?
Multiple sclerosis, Guillain-Barré syndrome and narcolepsy from epidemiological perspective

SUNDAY 14 April 2019

Symposia

16:00-18:00, Hall L
Influence of the microbiome on drugs, bugs, and us
co-organised with the ESCMID Study Group ESGHAMI
Corinne Maurice (Canada)
Ménage à trois in the human gut: interactions between the host, bacteria, and bacteriophages
Meriem Messaoudene (Canada)
How gut microbiome influences efficacy of immunotherapy
Vincent Young
Restoring the gut microbiome: profile vs function
Peter M. Hawkey (United Kingdom)
Legal and ethical aspects of modifying the microbiota

16:00-18:00, Hall K
Innovative application of transcriptomics to biomarkers in infection
Gerhard Walzl (South Africa)
Progress in diagnostic and prognostic tuberculosis RNA signatures
Leandra Linhares-Lacerda (Brazil)
RNA biomarkers in Chagas disease
Timothy Minogue (United States)
miRNAs in Ebola virus disease
Jethro Herberg (United Kingdom)
Host RNA signatures for syndromic diagnosis in febrile children
SUNDAY 14 April 2019

Educational Workshops

8:45-10:45, Hall C
Antifungal therapy: combine or not combine, this is the question!
co-organised with the ESCMID Study Groups EFISG and ESGB
Chair: Kieren Marr (United States)
Mario Fernandez Ruiz (Spain)
In vitro antifungal susceptibility and genomics to predict outcomes in fungal infections
Dimitrios P. Kontoyiannis (United States)
The case pro combination therapy
Federico Pea (Italy)
Combination antifungal treatment is usually not needed
Interactive panel discussion

13:30-15:30, Hall D
We need to improve vaccine coverage
coad-organised with the French Infectious Disease Society (SPLIF)
Olivier Epaullard (France)
Vaccine hesitancy: what an ID specialist can do
Adam Finn (United Kingdom)
Vaccine policy in children
Helena Maltezou (Greece)
Vaccine policy for healthcare workers
Interactive panel discussion

SUNDAY 14 April 2019

Educational Workshops

13:30-18:00, Hall I
Outbreak simulation exercise: who does what and why in case of an infectious disease outbreak
coad-organised with the ESCMID Study Group ESGPHM, the Trainees Association of ESCMID (TAE) and the ESCMID Task Force for Emerging Infections (EITaF)
Christian Winter (Germany)
Introduction outbreak exercise
Sergey R. Eremin (Switzerland)
Outbreak exercise
Caroline Rönnberg (Sweden)
Outbreak exercise
Alma Tostmann (Netherlands)
Outbreak exercise
Lieke B. van Alphen (Netherlands)
Outbreak exercise and result
Tim Brooks (United Kingdom)
How to get rapid access to “special diagnostics” for unusual or exotic agents?
Katrin Leitmeyer (Sweden)
Roles and responsibilities in an infectious disease outbreak
Interactive panel discussion
SUNDAY 14 April 2019

Educational Workshops

16:00-18:00, Hall C
Controversies in the management of hospital-acquired pneumonia
Antoni Torres (Spain)
Andre Kalil (United States)
Ignacio Martin-Loeches (Ireland)
Mark L. Metersky (United States)
Case presentations with discussion of guideline recommendations

SUNDAY 14 April 2019

Oral sessions

8:45-10:45, Hall D
Transplantation complete but viruses lurking
8:45-10:45, Hall M
Acinetobacter: persistence and resistance
11:00-12:00, Hall C
Other fungi exist!
11:00-12:00, Hall D
Optimising antibiotic use and outcome prediction in community-acquired pneumonia
11:00-12:00, Hall F
Antibiotics play with host cells: modulation of immune response and drug subcellular distribution
11:00-12:00, Hall I
New insights in bone infections
11:00-12:00, Hall L
Unconventional approaches to skin infections
11:00-12:00, Hall M
Mechanisms at play in biofilm associated infections
11:00-12:00, Hall N
Dengue: old disease, new challenges
13:30-14:30, Hall B
Travelling microorganisms in a world of travel
13:30-15:30, Hall J
Polymyxin resistance around the globe
13:30-15:30, Hall M
Novel Antimicrobial agents and discovery strategies
SUNDAY 14 April 2019

MiniOral Flash sessions

7:30-8:30, Hall K
Hospital antimicrobial stewardship: news from the world

14:45-15:45, Hall F
Beta-lactamases: still emerging after all these years

SUNDAY 14 April 2019

MiniOral ePoster sessions

11:00-12:00
Molecular diagnostics: answers at the right time

11:00-12:00
The diversity of international health aspects

11:00-12:00
Emerging data in non-tuberculous

13:30-14:30
Risks and outcomes of MDR Gram-negative infection

14:45-15:45
Epidemycology

14:45-15:45
Zoonoses: from reservoirs to patients

14:45-15:45
Getting rid of (multidrug-resistant) pathogens from the environment

14:45-15:45
Performance and utility of broad-range molecular diagnostics
MONDAY 15 April 2019

Keynote lectures

11:00-12:00, Hall A
Lalita Ramakrishnan (United Kingdom)
*Lessons for TB treatment from the zebrafish*

13:30-14:30, Hall A
Jean-Michel Pawlotsky (France)
*Hepatitis B therapy pipeline: how far are we from cure?*

"Year in…"

11:00-12:00, Hall H
*Nasia Safdar (United States)*
*Margreet C. Vos (Netherlands)*

MONDAY 15 April 2019

Meet-the-Expert

7:30-8:30, Hall B
*What I think should be the standard in diagnosing human mycoplasma infections*
co-organised with the ESCMID Study Group ESGMAC
*Cecile Bebear (France)*
*Jonas M. Winchell (United States)*

7:30-8:30, Hall C
*Difficulties to diagnose invasive fungal infection in paediatric patients*
co-organised with the ESCMID Study Group EFISG
*Elio Castagnola (Italy)*
*Thomas Lehrnbecher (Germany)*

7:30-8:30, Hall D
*EUCAST frequently asked questions*
co-organised with the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
*Rafael Canton Moreno (Spain)*

7:30-8:30, Hall K
*The Endocarditis Team: let’s make it work!*
co-organised with ESCMID Study Group ESGBIES
*Susan Rehm (United States)*
*Siegbert Rieg (Germany)*
MONDAY 15 April 2019

Meet-the-Expert

7:30-8:30, Hall C
How to manage orthopaedic implant infection? Real-life clinical case discussion
co-organised with the ESCMID Study Group ESGIAI
Martin McNally (United Kingdom)
Marjan Wouthuyzen-Bakker (Netherlands)

7:30-8:30, Hall J
How to use Point-of-Care tests in microbiology: European versus USA experiences
Robin Patel (United States)
Maurizio Sanguinetti (Italy)

7:30-8:30, Hall G
How and when should PCR be used in the diagnosis of C. difficile infection?
co-organised with the ESCMID Study Group ESGCD
Ferric C. Fang (United States)
Maja Rupnik (Slovenia)

7:30-8:30, Hall D
How to implement effective antimicrobial stewardship measures in the era of MDR and XDR pathogens
co-organised with the Hellenic Society for Chemotherapy
Ana Gales (Brazil)
Maddalena Giannella (Italy)

MONDAY 15 April 2019

Symposia

8:45-10:45, Hall H
Hot topics in hepatitis A-E
co-organised with the European Centre for Disease Prevention and Control (ECDC) and the ESCMID Study Groups ESGPHM, ESGVH, ESGIB, EFWISG and ESGVM
Ettore Severi (Sweden)
Molecular surveillance of HAV for multi-country outbreak detection
Cihan Yurdaydin (Turkey)
New treatment options for hepatitis delta
Tarik Asselah (France)
Hepatitis C: beyond the liver
Cornelia Adlhoch (Sweden)
HEV: the One Health approach

8:45-10:45, Hall D
Host-directed therapies for infectious diseases
co-organised with the ESCMID Study Group ESGICH
Thierry Calandra (Switzerland)
Host-directed therapies as adjunct treatment options for sepsis
Joshua A. Hill (United States)
Host-directed therapies as adjunct treatment options for viral infections
Nina Khanna (Switzerland)
Adoptive immunotherapy: the time has come?
Jay A. Fishman (Unites States)
Combating infection in immunotherapy and immunocompromised hosts
MONDAY 15 April 2019
Symposia

8:45-10:45, Hall B
Hot issues in bacterial infections in cancer patients
Diana Averbuch (Israel)
Any news in the epidemiology of microorganisms causing febrile neutropenia?
Carlota Gudiol (Spain)
Empiric antibiotic treatment of high-risk neutropenia in the era of multidrug-resistant Gram-negative bacteria
David Greenberg (United States)
Whole genome sequencing for detection of antibiotic resistance markers in bacteraemic leukaemia patients
TBA
Faecal microbiota transplantation to eradicate multidrug-resistant bacteria in cancer patients

8:45-10:45, Hall J
@mobilemicrobiologylaboratory
Snjezana Zidovec Lepej (Croatia)
Diagnostic portable instruments in microbiology: current status
David Ong (Netherlands)
Smart phones as mobile microbiological laboratories
Mario Poljak (Slovenia)
Drones as mobile microbiological laboratories
Emmanuelle Cambau (France)
Use of sniffing animals in diagnostic microbiology

MONDAY 15 April 2019
Symposia

8:45-10:45, Hall C
Advances in antifungal therapy co-organised with the ESCMID Study Group EFISG, the International Immunocompromised Host Society (ICHS) and the Trainees Association of ESCMID (TAE)
Cornelia Lass-Flörl (Austria)
Emergence of antifungal resistance and the promise of new antifungal agents
Jeremy Day (Viet Nam)
Best options in cryptococcosis
Ana Alastruey-Izquierdo (Spain)
Fusarium: a significant emerging mould
Patricia Munoz (Spain)
Antifungal stewardship programmes in the immunocompromised host
MONDAY 15 April 2019

Symposia

11:00-12:00, Hall E

**Monkeypox: management issues of an emerging viral infection**
Chikwe Ihekwezu (Nigeria)

*Lessons from African monkeypox outbreaks*
Mike Beadsworth (United Kingdom)

**Imported monkeypox**

11:00-12:00, Hall K

**Active or passive surveillance of Vaccine-Preventable bacterial Diseases (VPD)?**
co-organised with the European Centre for Disease Prevention and Control (ECDC)
Camelia Savulescu (France)

*Active surveillance of VPD: examples of the SPIDNET and PERTINENT projects*
Arto A. Palmu (Finland)

*Passive surveillance as basis for secondary use of register-based VPD data*

11:00-12:00, Hall J

**Advances in Clostridioides difficile prevention**
co-organised with the ESCMID Study Group ESGCD and the European Committee on Infection Control (EUCIC)
Pete Kinross (Sweden)

*The ECDC CDI surveillance protocol and European CDI surveillance data*
Sarah Tschudin-Sutter (Switzerland)

*C. difficile: does early treatment and choice of compound prevent transmission?*

---

MONDAY 15 April 2019

Symposia

11:00-12:00, Hall N

**Burden and cost of healthcare-associated infections and antimicrobial resistance**
co-organised with the European Committee on Infection Control (EUCIC)
Carolyn Tarrant (United Kingdom)

*What are we measuring, and is it making patients safer?*
Rasmus Leistner (Germany)

*How to improve analysis of costs of antimicrobial resistant infections using your hospital data*

11:00-12:00, Hall B

**Hot topics in antimicrobial stewardship**
co-organised with the World Health Organization (WHO), AMR Secretariat
Alison H. Holmes (United Kingdom)

*How leadership can influence antimicrobial stewardship*
Marlies Hulscher (Netherlands)

*Resources required for effective stewardship*

13:30-14:30, Hall B

**Emerging resistance in Gram-positives: what is left?**
Jose Munita (Chile)

*Are we losing it all? Daptomycin and linezolid resistance in enterococci*
Emilia Cercenado (Spain)

*Epiphenomenon or clinical relevance? Linezolid resistance in staphylococci*
MONDAY 15 April 2019
Symposia

13:30-14:30, Hall J
GEORG PETERS MEMORIAL SESSION
Coagulase-negative staphylococci: the new, stealthy superbugs
co-organised with ESCMID Study Groups ESGEM and ESGS
Benjamin P. Howden (Australia)
*Global spread of near pan-drug resistant lineages of Staphylococcus epidermidis*

Marine Butin (France)
*Worldwide dissemination of a multidrug-resistant Staphylococcus capitis clone in neonatal ICUs*

13:30-15:30 Hall K
Global health: Asian update
Direk Limmathurotsakul (Thailand)
*Melioidosis*

Sophie Yacoub (United Kingdom)
*Dengue Fever*

Priscilla Rupali (India)
*Enteric Fever*

J. Kevin Baird (Indonesia)
*Malaria*

13:30-15:30, Hall N
New antimicrobial targets: making friends with the enemy?
Jose M. Rodriguez Martinez (Spain)
*Resistance reversion by targeting the SOS response*

Roy Kishony (Israel)
*Evolutionary strategies to reverse antibiotic resistance*

Morten Sommer (Denmark)
*Collateral sensitivity and resistance*

Livia Leoni (Italy)
*Repurposing old drugs for new anti-virulence strategies: a Pseudomonas aeruginosa story*
MONDAY 15 April 2019
Symposia

14:45-15:45, Hall J
More about Candida auris: a killer yeast here to stay?
co-organised with ESCMID Study Groups EFISG and ESGNI
Dimitrios P. Kontoyiannis (United States)
Worldwide epidemiology and burden of Candida auris
Elisabeth Presterl (Austria)
Are special infection control measures needed for Candida auris?

14:45-15:45, Hall B
CRISPR–Cas revolution
Jonathan Gootenberg (United States)
CRISPR–Cas based diagnostics: nucleic acid detection with Cas12 and Cas13
Ben Berkhourt (Netherlands)
CRISPR–Cas based therapy of viral persistent infections

16:00-18:00, Hall J
Phage therapy’s coming of age: progress towards the application of bacteriophages in the treatment of infectious diseases
ASM-ESCMID joint symposium
Chair: Robin Patel (United States)
Carolyn Teschke (United States)
How to build a phage
Sarah Kuhl (United States)
Emerging clinical uses of phage therapy
Knut Drescher (Germany)
Predicting response to bacteriophages: AMR meets APR
Daniel De Vos (Belgium)
Barriers to widespread use of bacteriophages

MONDAY 15 April 2019
Symposia

16:00-18:00, Hall B
Multidrug-resistant Gram-negatives in the community: a major problem
Sho Saito (Japan)
Shaping the problem of multidrug-resistant Gram-negatives in the community: how big is the problem?
Dora Szabo (Hungary)
Molecular insights into the spread of resistance genes in the community: clones, mobile genetic elements or both?
TBA
Main drivers for community spread of resistance genes among Gram-negatives
Lior Nesher (Israel)
Interventions to control the spread of multidrug-resistant Gram-negatives in the community

16:00-18:00, Hall A
Focus on sepsis and septic shock: new data co-organised with the International Sepsis Forum (ISF)
ISF award lecture
Thierry Calandra (Switzerland)
What’s really hot in sepsis care 2019?
Tom van der Poll (Netherlands)
Sepsis: redefining the syndrome based on biomarkers
Kathryn M. Rowan (United Kingdom)
The changing epidemiology of sepsis
Pierluigi Viale (Italy)
Starting a sepsis team at your institution
MONDAY 15 April 2019

Educational Workshops

8:45-10:45, Hall E
Update on travel vaccines and prophylaxis
co-organised with the Trainees Association of
ESCMID (TAE) and the ESCMID Study Group
ESGITM

Lisa Ford (United Kingdom)
Vaccines for the healthy adult traveller and
the elderly or immunocompromised traveller

Martin P. Grobusch (Netherlands)
Vaccines for the pregnant traveller and the
small child traveller

Patricia Schlagenhauf (Switzerland)
Malaria prophylaxis for all?

Interactive panel discussion

8:45-10:45, Hall G
How to develop guidance documents in
clinical microbiology and infectious diseases

Benedikt Huttner (Switzerland)
Guidelines and other guidance documents in
infectious diseases and clinical microbiology: a
taxonomy and critical appraisal

Luigia Scudeller (Italy)
The GRADE system in the infectious diseases
field: specific issues in the assessment of
quality of the evidence

Mariska MG Leeflang (Netherlands)
From evidence to recommendations in the
field of infectious disease: issues in the GRADE
approach

Sheldon Stone (United Kingdom)
Proposals for adapting the GRADE approach
to the clinical microbiology and infectious
diseases field

MONDAY 15 April 2019

Educational Workshops

8:45-10:45, Hall F
Prevention and management of tuberculosis
in non-HIV-immunocompromised hosts
co-organised with the ESCMID Study Group
ESGMYC

Cybele L. R. Abad (Philippines)
Prevention and management of tuberculosis
in solid organ transplantation

Judith Bruchfeld (Sweden)
Prevention and management of tuberculosis
associated with biologicals

Sandra Arend (Netherlands)
What do the guidelines say?

Interactive panel discussion

13:30-15:30, Hall D
Update on diagnosis and treatment of non-
tuberculous mycobacteria (NTM)

Emmanuelle Cambau (France)
Diagnosis of NTM infections

Charles L. Daley (United States)
Treatment of NTM

Miguel Santin (Spain)
Challenging clinical cases of NTM

Interactive panel discussion
MONDAY 15 April 2019

Educational Workshops

13:30-18:00, Hall H
Progress in Infective Endocarditis (IE)
co-organised with the ESCMID Study Group ESGBIES
José M. Miró Meda (Spain)
Endocarditis: brief overview of recent progresses and challenges
Laurens Liesenborghs (Belgium)
Staphylococcus aureus manipulates coagulation to initiate endocarditis
Bernard Iung (France)
New imaging techniques in the diagnosis of infective endocarditis
Annette Moter (Germany)
Molecular imaging after valve surgery for culture negative IE
Barbara Hasse (Switzerland)
The nightmare of Mycobacterium chimaera
Margaret Hannan (Ireland)
Diagnosis and management of infection in cardiac assist devices
Emanuele Durante Mangoni (Italy)
What’s new in the antibiotic treatment of endocarditis?
Bruno Hoen (France)
What is the right timing for valve surgery in IE?

MONDAY 15 April 2019

Educational Workshops

13:30-18:00, Hall G
Fast and furious in infection control: how to be successful in seven steps!
co-organised with the European Committee on Infection Control (EUCIC)
Jan A. J. W. Kluymans (Netherlands)
The EUCIC talk: One Health approach in infection control
Nico T. Mutters (Germany)
Spotting mistakes in infection control: 67 y.o. is admitted to the hospital....
Eli Perencevich (United States)
First: build up an efficient, targeted local surveillance system
Maaike S. M. van Mourik (Netherlands)
Second: Connect surveillance data with clinical and radiological data
Walter Zingg (Switzerland)
Third: Organise information flow among infection control, antibiotic stewardship, and microbiology teams
Ben S. Cooper (Thailand)
Fourth: Planning infection control interventions using modelling and analysis of patients transfers
Sarah Tschudin-Sutter (Switzerland)
Fifth: Define goals and population for decolonisation strategies: differentiating among species and susceptibility patterns
Stephanie J. Dancer (United Kingdom)
Six: Infection control of the hospital environment: instruments, water, bedding, companion animals, ... and now also air: what, when, and how?
Andrew James Stewardson (Australia)
Seventh: Now you are ready to demonstrate that you have been successful: how to choose your outcomes?
Interactive panel discussion
MONDAY 15 April 2019

Educational Workshops

13:30-15:30, Hall C
Publishing research results: take advice with the editors
Chair: Robert C. Read (United Kingdom)
John S. McConnell (United Kingdom)
The role of journals and editors nowadays
Sharon Bloom (United States)
Journal selection: Changing options and risks for authors seeking to publish
Leonard Leibovici (Israel)
Why was my article rejected?
J. Peter Donnelly (Netherlands)
Can I appeal?
Ursula Hofer (United Kingdom)
How to write an authoritative review

13:30-15:30, Hall I
Device-related central nervous system (CNS) infections
co-organised with ESCMID Study Groups ESGIAI and ESGIB
Roland Nau (Germany)
PK/PD of anti-infective agents in the CNS
Diederik van de Beek (Netherlands)
Infections associated with CSF shunts, and CSF drains
Loreen Herwaldt (United States)
Deep brain stimulation hardware-related infections
Carmen Cabellos (Spain)
Management of device-related CNS infections

13:30-15:30, Hall L
MARK SHIRTLIFF MEMORIAL SESSION
Experimental models for chronic biofilm-related infections as surrogates for clinical testing
co-organised with the ESCMID Study Group ESGB
Birthje V. Kjellerup (United States) and Thomas Bjarnsholt (Denmark)
In memoriam Mark Shirtliff
Kasper N. Kragh (Denmark)
In vitro models – from planktonic to sessile lifestyle
Oscar Murillo (Spain)
Foreign body related models
Kendra P. Rumbaugh (United States)
Non-foreign body related in vivo biofilm models
Interactive panel discussion

16:00-18:00, Hall K
Clinical tropical medicine: management of acute severe infection
Nicholas White (Thailand)
Severe malaria
Andrea Boggild (Canada)
Weil’s disease
Björn Blomberg (Norway)
Haemorrhagic fever
George O. Akpede (Nigeria)
Lassa fever
Guy Thwaites (Vietnam)
Tropical brain infections
MONDAY 15 April 2019

Oral sessions

8:45-10:45, Hall A  
Why should I get vaccinated?

11:00-12:00, Hall C  
Infection in solid organ transplant

11:00-12:00, Hall F  
Clinical metagenomics: practical applications

11:00-12:00, Hall G  
Risk factors and prediction rules for ESBLs and carbapenemase producers: step further

11:00-12:00, Hall L  
Secrets of *Acinetobacter baumannii*’s virulence

11:00-12:00, Hall M  
Treatment of parasitic infections

13:30-14:30, Hall E  
Immunotherapy and infection

13:30-15:30, Hall F  
Practical aspects of implementing WGS

13:30-15:30, Hall M  
New therapeutic strategies in viral infections

16:00-18:00, Hall E  
*Klebsiella pneumoniae*: emergence of high-risk clones

16:00-18:00, Hall L  
Cutting edge in tuberculosis

16:00-18:00, Hall F  
Pathogenesis and treating of persistence staphylococcal infection

Chairs:  
Cristina Prat Aymerich (Spain)  
Estee Torok (United Kingdom)

---

MONDAY 15 April 2019

MiniOral ePoster sessions

11:00-12:00  
Invasive pneumococcal disease: serotypes and vaccination

11:00-12:00  
Antifungals: novel drugs, novel dosing

11:00-12:00  
The art of clinical microbiome studies

13:30-14:30  
Translational PK/PD to guide dosing

13:30-14:30  
News in fungal diagnostics

13:30-14:30  
Rapid AST: how fast can you go?

14:45-15:45  
Endocarditis: myths and reality

14:45-15:45  
Epidemiology and outcomes of bloodstream infections due to Gram-negatives

14:45-15:45  
Advanced techniques for tracking virulence and persistence
TUESDAY 16 April 2019

**Keynote lectures**

11:00-12:00, Hall A
Eske Willerslev (Denmark)
*What ancient DNA studies tell us about human infection?*

13:30-14:30, Hall A
Mercedes Tatay (Switzerland)
*MSF’s perspective on medical ethics in the context of emergency response*

**Clinical Grand Round**

8:45-10:45, Hall A
Moderator: Robert C. Read (United Kingdom)
Experts:
- Maristela Pinheiro Freire (Brazil)
- Maddalena Giannella (Italy)
- Dimitrios P. Kontoyiannis (United States)
- David L. Paterson (Australia)
- Jesús Rodríguez-Baño (Spain)
- Shiranee Sriskandan (United Kingdom)

Case presenters:
- Cansu Cimen (Turkey)
- Ana V. Halperin (Spain)
- Synne Jenum (Norvegia)
- John Lam (Canada)
- Nathan Peiffer-Smadja (France) and Sarah Dellièvre (France)"
- Madeeha Shams (United States)
- Anastasia Theodosiou (United Kingdom)

TUESDAY 16 April 2019

**Meet-the-Expert**

7:30-8:30, Hall M
*Which host response assays are ready to get implemented in clinical practice?*
Giovanni Delogu (Italy)
TBA

7:30-8:30, Hall C
*What is needed for paving the way to HCV elimination?*
co-organised with the European Association for the Study of the Liver (EASL)
Markus Cornberg (Germany)
Jean-Michel Pawlotsky (France)

7:30-8:30, Hall J
*Burning questions concerning the antimicrobial therapy of sepsis*
co-organised with ESCMID Study Groups ESGAP and ESGBIES
Johan Mouton (Netherlands)
David L. Paterson (Australia)

7:30-8:30, Hall F
*How to define fungal infection in critically ill patients: new ESCMID guidance?*
co-organised with ESCMID Study Groups ESGCIP and EFISG
Matteo Bassetti (Italy)
Cornelia Lass-Flörl (Austria)

7:30-8:30, Hall G
*How I manage vascular graft infection*
co-organised with the ESCMID Study Group ESGIAI
Efthymia Giannitsioti (Greece)
Eric Senneville (France)
TUESDAY 16 April 2019

Meet-the-Expert

7:30-8:30, Hall D
How to implement and use metagenomics in infectious disease diagnostics and management?
co-organised with the Turkish Society of Clinical Microbiology
Koray Ergunay (Turkey)
Justin O’Grady (United Kingdom)

7:30-8:30, Hall B
How to best manage difficult-to-treat infectious diseases in migrants
co-organised with ESCMID Study Group ESGITM and the Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD)
Susanna Capone (Italy)
Christian Wejse (Australia)

7:30-8:30, Hall E
How to manage immunocompromised patients with central nervous system infection?
co-organised with ESCMID Study Groups ESGBIES and ESGICH
Paola Cinque (Italy)
Oriol Manuel (Switzerland)

TUESDAY 16 April 2019

Symposia

8:45-10:45, Hall C
Diagnosis and management of bloodstream infections: a critical analysis to optimise patient care
Harald Seifert (Germany)
Molecular versus culture-based approaches in bloodstream infection diagnosis: what to choose?
Brigitte Lamy (France)
Minutes count: rapid detection/identification and susceptibility testing in bloodstream infections
Luis E. Lopez-Cortes (Spain)
Bundles of care and streamlining in bloodstream infection
Dafna Yahav (Israel)
Duration of treatment for bloodstream infections

8:45-10:45, Hall D
Global health: African update
co-organised with the French Infectious Diseases Society (SPILF) and the ESCMID Study Group EFWISG
André Spiegel (Madagascar)
Lessons learnt from the 2017/18 plague outbreak in Madagascar
Mamoudou Harouna Djingarey (Democratic Republic of the Congo)
Monkeypox in Africa: emerging disease or better recognition?
Chikwe Ihekweazu (Nigeria)
Experiences with Lassa fever/VHF control networking
Melita Gordon (Malawi)
New types of African Salmonella causing lethal infection
TUESDAY 16 April 2019

Symposia

8:45-10:45, Hall J
Individualised antimicrobial therapy for the future
co-organised with ESCMID Study Groups EPASG and ESGAP
Timothy Rawson (United Kingdom)
New technologies to support dose optimisation: where will we be in 2024?
Lena Friberg (Sweden)
Predicting antimicrobial pharmacodynamics: moving beyond MIC-based indices
Gauri Rao (United States)
Individualised dosing: what about the immune status?
Angela Huttner (Switzerland)
Can TDM-guided therapy reduce antimicrobial resistance?

8:45-10:45, Hall G
The role of the healthcare environment in nosocomial infections
co-organised with the ESCMID Study Group ESGNI and the European Committee on Infection Control (EUCIC)
Cesira Pasquarella (Italy)
Microbial air contamination in hospital environment: what about standards?
Stephanie J. Dancer (United Kingdom)
Risk-based cleaning of the hospital environment
Janet Nale (United Kingdom)
Bacteriophages and Clostridioides difficile: what is the potential?
Elisabeth Presterl (Austria)
How to build the houses of health: conception, planning, construction and building hospitals

11:00-12:00, Hall E
Getting in and out of Gram-negative bacteria: a molecular view
Mathias Winterhalter (Germany)
Antibiotic transport through porins: how does it work?
Martin Picard (France)
Structural and functional studies of in vitro fully assembled Pseudomonas aeruginosa efflux pumps

11:00-12:00, Hall G
Tackling persistent infections with innovative therapies and nanomaterials
co-organised with ESCMID Study Groups ESGB and ESGIAI
Nikos Kehagias (Spain)
Antimicrobial flexible polymers for use in hospital environments
Joana Azeredo (Portugal)
Exploiting bacteriophages and derived enzymes to control infectious biofilms
TUESDAY 16 April 2019

Symposia

13:30-15:30, Hall E
Bacterial resistance: evolution, plasmids and fitness
co-organised with ESCMID Study Groups ESGS, EFWISG and ESGVM

Barry Kreiswirth (United States)
Processes driving the evolution of antibiotic resistance

Diarmaid Hughes (Sweden)
How resistance development impact bacterial fitness

Laura J. V. Piddock (United Kingdom)
Plasmid-encoded resistance: not necessarily a fitness burden

Heike Schmitt (Netherlands)
TBA

TUESDAY 16 April 2019

Educational Workshops

8:45-10:45, Hall K
Challenges for clinical study designs and evidence in infectious diseases

Luigia Scudeller (Italy)
Limitations of randomised trials. Is the king naked?

Mical Paul (Israel)
Meta-analysis: friend or foe

Marc J. Bonten (Netherlands)
Innovative clinical trial designs

Interactive panel discussion
TUESDAY 16 April 2019

Educational Workshops

13:30-15:30, Hall C
Changing perspectives in the treatment of **C. difficile** infection (CDI)
co-organised with ESCMID Study Groups ESGCD and ESGHAMI
Stuart Johnson (United States)
*Recent changes in CDI treatment guidelines*

Maria Vehreschild (Germany)
*Various forms of faecal microbiota transplantation for recurrent CDI*

Tanya Monaghan (United Kingdom)
*What is the target group for antitoxin treatment to prevent CDI?*

*Interactive panel discussion*

13:30-15:30, Hall D
Neutropenia: the ups and downs of antibiotic therapy
co-organised with the ESCMID Study Group ESGICH
Eric J. Bow (Canada)
*Neutropenic fever and ghost-infectious diseases: no pathogens, but still antibiotics?*

Genovefa Papanicolaou (United States)
*Neutropenic fever and non-infectious causes: no pathogens, but still antibiotics?*

Inge C. Gyssens (Netherlands)
*Neutropenic fever, no pathogen, no antibiotics: is it possible?*

*Interactive panel discussion*

TUESDAY 16 April 2019

Oral sessions

8:45-10:45, Hall M
Emerging viral infections: what’s around the corner

8:45-10:45, Hall H
MRSA, VRE and beyond

11:00-12:00, Hall B
Does type matter? News from the changing Influenza Vaccine landscape

11:00-12:00, Hall K
Insights into gut resistome

13:30-15:30, Hall B
Molecular and genomic epidemiology of **S. aureus**

13:30-15:30, Hall F
Neuroinvasive viral infection

13:30-15:30, Hall G
Know your enemy: *Aspergillus*

13:30-15:30, Hall I
Strategies for testing and destroying biofilm

13:30-15:30, Hall J
Multimodal approaches to control MDR Gram-negative transmission and infection

13:30-15:30, Hall K
Focus on malaria

13:30-15:30, Hall L
PK/PD to guide dosing in special populations

13:30-15:30, Hall M
Preventing surgical site infections in the era of increased antibiotic resistance

13:30-15:30, Hall
Interventions to reduce morbidity and mortality of bloodstream infections
TUESDAY 16 April 2019

MiniOral Flash sessions

11:00-12:00, Hall J
Infection in immunocompromised host

11:00-12:00, Hall D
Infections in mothers and newborns

11:00-12:00, Hall F
Viral hepatitis: new trends, old challenges

14:45-15:45, Hall F
Optimised diagnosis of bacterial infection

TUESDAY 16 April 2019

MiniOral ePoster sessions

11:00-12:00
Haemorrhagic fevers: from Lassa to Ebola

11:00-12:00
Defining exposure, efficacy and safety of new antimicrobial agents

11:00-12:00
Implementing and validating interventions for infection prevention

11:00-12:00
Resistance and persistence in Gram-negatives

13:30-14:30
What's hot in HIV/AIDS?

13:30-14:30
What's hot in respiratory viruses?

13:30-14:30
Biomarker and molecular diagnosis of parasitic diseases